Resverlogix
Late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses.
Launch date
Employees
Market cap
CAD16.6m
Enterprise valuation
CAD29m (Public information from Sep 2024)
Share price
CAD0.07 RVX.TO
Calgary Alberta (HQ)
Authorizing premium user...